EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

Journal of Hepatology

Volumn 67, Issue 2, 2017, Pages 370-398

  Lampertico, Pietro ^a   Agarwal, Kosh ^a   Berg, Thomas ^a   Buti, Maria ^a   Janssen, Harry L A ^a   Papatheodoridis, George ^a   Zoulim, Fabien ^a   Tacke, Frank ^a  

^a NONE

Author keywords

EASL guidelines; Entecavir; HBsAg; HBV DNA; HBV reactivation; Hepatitis B; Hepatocellular carcinoma; Interferon; Mother to child transmission; TAF; Tenofovir; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; ALPHA INTERFERON; ANTIVIRUS AGENT;

ACUTE HEPATITIS B; ANTIVIRAL RESISTANCE; ARTICLE; BILE DUCT DISEASE; BIOCHEMICAL ANALYSIS; CHRONIC HEPATITIS B; CLINICAL ASSESSMENT; CLINICAL FEATURE; DECOMPENSATED LIVER CIRRHOSIS; DIALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GENETIC VARIABILITY; GRAFT RECIPIENT; HEALTH CARE PERSONNEL; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION PREVENTION; KIDNEY GRAFT; LIFE CYCLE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MANAGED CARE; MEDICAL HISTORY; MIXED INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS REPLICATION; DRUG EFFECTS; EUROPE; FEMALE; GENETICS; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MEDICAL SOCIETY; PREVENTION AND CONTROL; VERTICAL TRANSMISSION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; EUROPE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; PREGNANCY; SOCIETIES, MEDICAL;

EID: 85017533115     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.03.021     Document Type: Article

References (247)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
2. Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 386 (2015), 1546–1555.
3. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
4. Ott, J.J., Stevens, G.A., Groeger, J., Wiersma, S.T., Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30 (2012), 2212–2219.
5. Chen, C.-L., Yang, J.-Y., Lin, S.-F., Sun, C.-A., Bai, C.-H., You, S.-L., et al. Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol 63 (2015), 354–363.
6. Coppola, N., Alessio, L., Gualdieri, L., Pisaturo, M., Sagnelli, C., Caprio, N., et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. Euro Surveill, 20, 2015, 30009.
7. Hampel, A., Solbach, P., Cornberg, M., Schmidt, R.E., Behrens, G.M., Jablonka, A., Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 59 (2016), 578–583.
8. Iqbal, K., Klevens, R.M., Kainer, M.A., Baumgartner, J., Gerard, K., Poissant, T., et al. Epidemiology of acute hepatitis B in the united states from population-based surveillance, 2006–2011. Clin Infect Dis 61 (2015), 584–592.
9. Ott, J.J., Horn, J., Krause, G., Mikolajczyk, R.T., Time trends of chronic HBV infection over prior decades – A global analysis. J Hepatol 66 (2017), 48–54.
10. Stanaway, J.D., Flaxman, A.D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet 388 (2016), 1081–1088.
11. Seeger, C., Mason, W.S., Molecular biology of hepatitis B virus infection. Virology 479–480 (2015), 672–686.
12. Tong, S., Revill, P., Overview of hepatitis B viral replication and genetic variability. J Hepatol 64 (2016), S4–S16.
13. Lucifora, J., Protzer, U., Attacking hepatitis B virus cccDNA–The holy grail to hepatitis B cure. J Hepatol 64 (2016), S41–S48.
14. Levrero, M., Zucman-Rossi, J., Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 64 (2016), S84–S101.
15. Kramvis, A., Genotypes and genetic variability of hepatitis B virus. Intervirology 57 (2014), 141–150.
16. Bertoletti, A., Ferrari, C., Adaptive immunity in HBV infection. J Hepatol 64 (2016), S71–S83.
17. Maini, M.K., Gehring, A.J., The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol 64 (2016), S60–S70.
18. Li, Y., Si, L., Zhai, Y., Hu, Y., Hu, Z., Bei, J.-X., et al. Genome-wide association study identifies 8p21.3 associated with persistent hepatitis B virus infection among Chinese. Nat Commun, 7, 2016, 11664.
19. Mason, W.S., Gill, U.S., Litwin, S., Zhou, Y., Peri, S., Pop, O., et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology 151 (2016), 986–998.
20. Kennedy, P.T., Sandalova, E., Jo, J., Gill, U., Ushirolumb, I., Tan, A.T., et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143 (2012), 637–645.
21. Cornberg, M., Wong, V.W., Locarnini, S., Brunetto, M., Janssen, H.L., Chan, H.L., The role of quantitative hepatitis B surface antigen revisited. J Hepatol 66 (2017), 398–411, 10.1016/j.jhep.2016.08.009.
22. Yang, R., Song, G., Guan, W., Wang, Q., Liu, Y., Wei, L., The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. J Virol Methods 228 (2016), 39–47.
23. Raffetti, E., Fattovich, G., Donato, F., Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int 36 (2016), 1239–1251.
24. Varbobitis, I., Papatheodoridis, G.V., The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol 22 (2016), 319–326.
25. Papatheodoridis, G.V., Chan, H.L., Hansen, B.E., Janssen, H.L., Lampertico, P., Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol 62 (2015), 956–967.
26. Arends, P., Sonneveld, M.J., Zoutendijk, R., Carey, I., Brown, A., Fasano, M., et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians. Gut 64 (2015), 1289–1295.
27. Papatheodoridis, G.V., Dalekos, G.N., Yurdaydin, C., Buti, M., Goulis, J., Arends, P., et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 62 (2015), 363–370.
28. Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 64 (2016), 800–806.
29. Brouwer, W., Hansen, B., Raffetti, E., Donato, F., Fattovich, G., The PAGE-B score stratifies chronic hepatitis B patients with compensated cirrhosis at high risk of hepatocellular carcinoma development with good accuracy. Hepatology 62 (Suppl.) (2015), 93A–207A.
30. Brouwer, W., van der Meer, A., Boonstra, A., Plompen, E., Pas, S., de Knegt, R., et al. The PAGE-B score accurately predicts clinical outcome and outperforms other biomarkers over 15 years of follow-up in a diverse cohort of chronic hepatitis B patients. Hepatology 62 (Suppl.) (2015), 93A–207A.
31. Li, Y., Huang, Y.S., Wang, Z.Z., Yang, Z.R., Sun, F., Zhan, S.Y., et al. Systematic review with meta-analysis: The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther 43 (2016), 458–469.
32. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63 (2015), 237–264.
33. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. Chinese J Evidence-Based Med 9 (2009), 8–11.
34. Su, T.-H., Hu, T.-H., Chen, C.-Y.C-L., Huang, Y.-H.Y.-W., Chuang, W.-L., Lin, C.-L.C.-C., et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 36 (2016), 1755–1764, 10.1111/liv.13253.
35. Lampertico, P., Invernizzi, F., Viganò, M., Loglio, A., Mangia, G., Facchetti, F., et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. J Hepatol 63 (2015), 1118–1125.
36. Kim, W.R., Loomba, R., Berg, T., Aguilar Schall, R.E., Yee, L.J., Dinh, P.V., et al. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer 121 (2015), 3631–3638.
37. Coffin, C.S., Rezaeeaval, M., Pang, J.X., Alcantara, L., Klein, P., Burak, K.W., et al. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther 40 (2014), 1262–1269.
38. Hosaka, T., Suzuki, F., Kobayashi, M.M., Seko, Y., Kawamura, Y., Sezaki, H., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 (2013), 98–107.
39. Su, T.-H., Hu, T.-H., Chen, C.-Y., Huang, Y.-H., Chuang, W.-L., Lin, C.-L., et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 36 (2016), 1755–1764.
40. Wu, C.-Y., Lin, J.-T., Ho, H.J., Su, C.-W., Lee, T.-Y., Wang, S.-Y., et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147 (2014), 143–151.
41. Papatheodoridis, G., Vlachogiannakos, I., Cholongitas, E., Wursthorn, K., Thomadakis, C., Touloumi, G., et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 63 (2016), 1481–1492.
42. Marcellin, P., Xie, Q., Paik, S.W., Flisiak, R., Piratvisuth, T., Petersen, J., et al. Effectiveness of peginterferon Alfa-2a therapy in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B: final results 3 years post-treatment of the prospective, global, observational S-collate study. J Hepatol 64 (2017), S598–S599.
43. Jacobson, I.M., Marcellin, P., Buti, M., Gane, E.J., Sievert, W., Tsai, N., et al. Factors associated with the lack of achievement of nor-mal ALT in chronic hepatitis B (CHB) patients treated with tenofovir DF (TDF) for up to 5 years. Hepatology, 56, 2012, 394A.
44. Spradling, P.R., Bulkow, L., Teshale, E.H., Negus, S., Homan, C., Simons, B., et al. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. J Hepatol 61 (2014), 785–791.
45. Chi, H., Arends, P., Reijnders, J.G., Carey, I., Brown, A., Fasano, M., et al. Flares during long-term entecavir therapy in chronic hepatitis B. J Gastroenterol Hepatol 31 (2016), 1882–1887.
46. Sonneveld, M.J., Zoutendijk, R., Flink, H.J., Zwang, L., Hansen, B.E., Janssen, H.L., Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 56 (2013), 100–105.
47. Kim, G.-A., Lim, Y.-S., An, J., Lee, D., Shim, J.H., Kim, K.M., et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut 63 (2014), 1325–1332.
48. Seto, W.-K., Cheung, K.-S., Wong, D.K.-H., Huang, F.-Y., Fung, J., Liu, K.S.-H., et al. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. J Gastroenterol 51 (2016), 487–495.
49. Perrillo, R.P., Martin, P., Lok, A.S., Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA, 313, 2015, 1617.
50. Di Bisceglie, A.M., Lok, A.S., Martin, P., Terrault, N., Perrillo, R.P., Hoofnagle, J.H., Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?. Hepatology 61 (2015), 703–711.
51. Mallet, V., van Bömmel, F., Doerig, C., Pischke, S., Hermine, O., Locasciulli, A., et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 16 (2016), 606–617.
52. Perrillo, R.P., Gish, R., Falck-Ytter, Y.T., American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 221–244.
53. Liu, J., Yang, H.-I., Lee, M.-H., Lu, S.-N., Jen, C.-L., Batrla-Utermann, R., et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 63 (2014), 1648–1657.
54. Kim, G.-A., Lee, H.C., Kim, M.-J., Ha, Y., Park, E.J., An, J., et al. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 62 (2015), 1092–1099.
55. Papatheodoridis, G.V., Manolakopoulos, S., Liaw, Y.F., Lok, A., Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. J Hepatol 57 (2012), 196–202.
56. Terrault, N.A., Bzowej, N.H., Chang, K.-M., Hwang, J.P., Jonas, M.M., Murad, M.H., et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (2016), 261–283.
57. Lok, A.S., McMahon, B.J., Brown, R.S., Wong, J.B., Ahmed, A.T., Farah, W., et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 63 (2016), 284–306.
58. Peng, C.-Y., Chien, R.-N., Liaw, Y.-F., Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol 57 (2012), 442–450.
59. Singal, A.K., Fontana, R.J., Meta-analysis: Oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 35 (2012), 674–689.
60. Boglione, L., D'Avolio, A., Cariti, G., Di Perri, G., Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. J Clin Virol 56 (2013), 167–169.
61. Mazzaro, C., Dal Maso, L., Urraro, T., Mauro, E., Castelnovo, L., Casarin, P., et al. Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISC. Dig Liver Dis 48 (2016), 780–784.
62. Marcellin, P., Ahn, S.H., Ma, X., Caruntu, F.A., Tak, W.Y., Elkashab, M., et al. Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150 (2016), 134–144.
63. Marcellin, P., Ahn, S.H., Chuang, W.-L., Hui, A.J., Tabak, F., Mehta, R., et al. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther 44 (2016), 1–10.
64. Lampertico, P., Soffredini, R., Viganò, M., Minola, E., Cologni, G., Rizzi, M., et al. 755 5-Year entecavir treatment in nuc-naïve, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics. J Hepatol 58 (2013), S306–S307.
65. Seto, W.K., Lam, Y.F., Fung, J., Wong, D.K., Huang, F.Y., Hung, I.F., et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol 29 (2014), 1028–1034.
66. Ono, A., Suzuki, F., Kawamura, Y., Sezaki, H., Hosaka, T., Akuta, N., et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 57 (2012), 508–514.
67. Luo, J., Li, X., Wu, Y., Lin, G., Pang, Y., Zhang, X., et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life. Int J Med Sci 10 (2013), 427–433.
68. Tanwandee, T., Charatcharoenwitthaya, P., Chainuvati, S., Chotiyaputta, W., Nimanong, S., Efficacy and safety of entecavir treatment of chronic hepatitis B patients in real-world clinical practice. Hepatology, 20, 2013, 672A.
69. Marcellin, P., Gane, E.J., Flisiak, R., Trinh, H.N., Petersen, J., Gure, S., et al. Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology 60 (2014), 313A–317A.
70. Petersen, J., Heyne, R., Mauss, S., Schlaak, J., Schiffelholz, W., Eisenbach, C., et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: A 3-year prospective field practice study in Germany. Dig Dis Sci 61 (2016), 3061–3071.
71. Tabernero, D., Sánchez-Tapias, J.M., Calleja, J.L., Moreira, V., Manzano, M.L., Crespo, J., et al. P1058 long-term efficacy of tenofovir in previously treated and naive patients. results from the spanish chronic hepatitis B registry (Ciberhep). J Hepatol, 60, 2014, S429.
72. Marcellin, P., Zoulim, F., Hézode, C., Causse, X., Roche, B., Truchi, R., et al. Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: A 3-year, prospective, real-world study in France. Dig Dis Sci 61 (2016), 3072–3083.
73. Lampertico, P., Soffredini, R., Yurdaydin, C., Idilman, R., Papatheodoridis, G.V., Mar-gariti, E., et al. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. Hepatology 58 (2013), 647A–705A.
74. Buti, M., Gane, E., Seto, W.K., Chan, H.L., Chuang, W.-L., Stepanova, T., et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1 (2016), 196–206.
75. Agarwal, K., Fung, S., Seto, W.K., Lim, Y.S., Gane, E., Janssen, H.L., et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96. J Hepatol, 66, 2017, S478.
76. Chan, H.L., Fung, S., Seto, W.K., Chuang, W.-L., Chen, C.-Y., Kim, H.J., et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1 (2016), 185–195.
77. Brunetto, M., Lim, Y.S., Gane, E., Seto, W.K., Osipenko, M., Ahn, S.H., et al. A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): efficacy and safety results at week 96. J Hepatol 66 (2017), S25–S26.
78. Custodio, J.M., Fordyce, M., Garner, W., Vimal, M., Ling, K.H., Kearney, B.P., et al. Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother 60 (2016), 5135–5140.
79. Lampertico, P., Chan, H.L., Janssen, H.L., Strasser, S.I., Schindler, R., Berg, T., Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 44 (2016), 16–34.
80. Gill, U.S., Zissimopoulos, A., Al-Shamma, S., Burke, K., McPhail, M.J., Barr, D.A., et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis 211 (2014), 1–9.
81. Maggi, P., Montinaro, V., Leone, A., Fasano, M., Volpe, A., Bellacosa, C., et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: A longitudinal study. J Antimicrob Chemother 70 (2014), 1150–1154.
82. Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H.W., et al. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol 66 (2016), 11–18.
83. Buti, M., Tsai, N., Petersen, J., Flisiak, R., Gurel, S., Krastev, Z., et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 60 (2015), 1457–1464.
84. Han, Y., Zeng, A., Liao, H., Liu, Y., Chen, Y., Ding, H., The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol 42 (2017), 168–175.
85. Ahn, J., Lee, H.M., Lim, J.K., Pan, C.Q., Nguyen, M.H., Ray Kim, W., et al. Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Aliment Pharmacol Ther 43 (2016), 134–144.
86. Law, S.-T., Lee, M.K., Li, K.K., Mok, C.K., Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 28 (2016), 193–198.
87. Coppolino, G., Simeoni, M., Summaria, C., Postorino, M.C., Rivoli, L., Strazzulla, A., et al. The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol 28 (2015), 393–402.
88. Chuang, W.L., Agarwal, K., Hwang, J.S., Caruntu, F., Wong, F., Hann, H.W., et al. Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks. J Hepatol, 66, 2017, S695.
89. Huhn, G.D., Tebas, P., Gallant, J., Wilkin, T., Cheng, A., Yan, M., et al. A randomized, open-label trial to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr 74 (2017), 193–200.
90. Mills, A., Arribas, J.R., Andrade-Villanueva, J., DiPerri, G., Van Lunzen, J., Koenig, E., et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16 (2016), 43–52.
91. Pozniak, A., Arribas, J.R., Gathe, J., Gupta, S.K., Post, F.A., Bloch, M., et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 71 (2016), 530–537.
92. Post, F.A., Tebas, P., Clarke, A., Cotte, L., Short, W., Abram, M.E., et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single arm, multicenter, open label phase 3 study. J AIDS 74 (2017), 180–184.
93. Papatheodoridis, G., Yurdaydin, C., Dalekos, G., Buti, M., Chi, H., Van Boemmel, F., The risk of hepatocellular carcinoma (HCC) is decreasing after the first 5 years of entecavir (ETV) or tenofovir (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients. Hepatology, 64 (Suppl.), 2016, 923A.
94. Papatheodoridis, G., Dalekos, G., Yurdaydin, C., Van Boemmel, F., Buti, M., Sypsa, V., et al. Hepatocellular carcinoma (HCC) is the only factor affecting the excellent survival of Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy. Hepatology 64 (Suppl.) (2016), 35A–36A.
95. Wong, G.L., Chan, H.L., Mak, C.W., Lee, S.K., Ip, Z.M., Lam, A.T., et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology 58 (2013), 1537–1547.
96. Lim, Y.-S., Han, S., Heo, N.-Y., Shim, J.H., Lee, H.C., Suh, D.J., Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs. lamivudine. Gastroenterology 147 (2014), 152–161.
97. Sarin, S.K., Kumar, M., Lau, G.K., Abbas, Z., Chan, H.L., Chen, C.J., et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10 (2016), 1–98.
98. Jeng, W.J., Sheen, I.S., Chen, Y.C., Hsu, C.W., Chien, R.N., Chu, C.M., et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 58 (2013), 1888–1896.
99. Zoulim, F., Locarnini, S., Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int 33 (2013), 116–124.
100. Zoulim, F., Locarnini, S., Management of treatment failure in chronic hepatitis B. J Hepatol 56 (2012), S112–S122.
101. Park, J.Y., Kim, C.W., Bae, S.H., Jung, K.S., Kim, H.Y., Yoon, S.K., et al. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int 36 (2016), 1108–1115.
102. Lim, Y.-S., Yoo, B.C., Byun, K.S., Kwon, S.Y., Kim, Y.J., An, J., et al. Tenofovir monotherapy vs. tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut 65 (2016), 1042–1051.
103. Zoulim, F., Białkowska-Warzecha, J., Diculescu, M.M., Goldis, A.E., Heyne, R., Mach, T., et al. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatol Int 10 (2016), 779–788.
104. Petersen, J., Ratziu, V., Buti, M., Janssen, H.L., Brown, A., Lampertico, P., et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 56 (2012), 520–526.
105. Sonneveld, M.J., Hansen, B.E., Piratvisuth, T., Jia, J., Zeuzem, S., Gane, E., et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58 (2013), 872–880.
106. Sonneveld, M.J., Brouwer, W.P., van der Meer, A.J., Posttreatment hepatitis B surface antigen seroreversion: the bane of combination therapy in chronic hepatitis B?. Gastroenterology 150 (2016), 1254–1255.
107. Lampertico, P., Maini, M., Papatheodoridis, G., Optimal management of hepatitis B virus infection – EASL Special Conference. J Hepatol 63 (2015), 1238–1253.
108. Chon, Y.E., Kim, D.J., Kim, S.G., Kim, I.H., Bae, S.H., Hwang, S.G., et al. An observational, multicenter, cohort study evaluating the antiviral efficacy and safety in korean patients with chronic hepatitis B receiving pegylated interferon-alpha 2a (Pegasys). Medicine, 95, 2016, e3026.
109. Lampertico, P., Viganò, M., Di Costanzo, G.G., Sagnelli, E., Fasano, M., Di Marco, V., et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 62 (2013), 290–298.
110. Chen, X., Chen, X., Chen, W., Ma, X., Huang, J., Chen, R., Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B. J Med Virol 86 (2014), 1705–1713.
111. Lampertico, P., Rothe, V., Caputo, A., Papatheodoridis, G.V., A baseline predictive tool for selecting HBeAg-negative chronic hepatitis B patients who have a high probability of achieving sustained immune control with peginterferon alfa-2a. Hepatology, 60, 2014, 1107A.
112. Lampertico, P., Messinger, D., Cornberg, M., Brunetto, M., Petersen, J., Kennedy, P., et al. A genotype-specific baseline score to predict response at 48 weeks post-treatment to peginterferon alfa-2a in patients with HBeAg-negative chronic hepatitis B. J Hepatol 64 (2016), S599–S600.
113. Sonneveld, M.J., Wong, V.W.-S., Woltman, A.M., Wong, G.L., Cakaloglu, Y., Zeuzem, S., et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142 (2012), 513–520.
114. Lampertico, P., Viganò, M., Cheroni, C., Facchetti, F., Invernizzi, F., Valveri, V., et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 57 (2013), 890–896.
115. Brunetto, M.R., Marcellin, P., Cherubini, B., Yurdaydin, C., Farci, P., Hadziyannis, S.J., et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 59 (2013), 1153–1159.
116. Sonneveld, M.J., Rijckborst, V., Zwang, L., Zeuzem, S., Jenny Heathcote, E., Simon, K., et al. Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. Antiviral Res 97 (2013), 312–317.
117. Rijckborst, V., Hansen, B.E., Ferenci, P., Brunetto, M.R., Tabak, F., Cakaloglu, Y., et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 56 (2012), 1006–1011.
118. Goulis, I., Karatapanis, S., Akriviadis, E., Deutsch, M., Dalekos, G.N., Raptopoulou-Gigi, M., et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 35 (2015), 1540–1548.
119. Marcellin, P., Bonino, F., Yurdaydin, C., Hadziyannis, S., Moucari, R., Kapprell, H.P., et al. Hepatitis B surface antigen levels: Association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 7 (2013), 88–97.
120. Papatheodoridis, G.V., Cornberg, M., Xie, Q., Lampertico, P., Burghaus, I., Bakalos, G., et al. Incidence and risk prediction of hepatocellular carcinoma: retrospective analysis of the S-collate study. Hepatol Int 11 (2017), S4–S5.
121. Liang, K.-H., Hsu, C.-W., Chang, M.-L., Chen, Y.-C., Lai, M.-W., Yeh, C.-T., Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 213 (2016), 966–974.
122. Lok, A.S., Trinh, H., Carosi, G., Akarca, U.S., Gadano, A., Habersetzer, F., et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 143 (2012), 619–628.
123. Zoulim, F., Carosi, G., Greenbloom, S., Mazur, W., Nguyen, T., Jeffers, L., et al. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 62 (2015), 56–63.
124. Chan, H.L., Chan, C.K., Hui, A.J., Chan, S., Poordad, F., Chang, T.-T., et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 146 (2014), 1240–1248.
125. Choi, H.N., Song, J.E., Lee, H.C., Jo, H.H., Lee, C.H., Kim, B.S., Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol 21 (2015), 24–31.
126. Maier, M., Liebert, U.G., Wittekind, C., Kaiser, T., Berg, T., Wiegand, J., Clinical relevance of minimal residual viremia during long-term therapy with nucleos(t)ide analogues in patients with chronic hepatitis B. PLoS One, 8, 2013, e67481.
127. Kim, S.S., Hwang, J.C., Lim, S.G., Ahn, S.J., Cheong, J.Y., Cho, S.W., Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 109 (2014), 1223–1233.
128. Ha, N.B., Ha, N.B., Trinh, H.N., Nguyen, H.A., Nguyen, K.K., Nguyen, M.H., Response to higher dose of entecavir 1.0 mg daily in patients with partial response to entecavir 0.5 mg daily. J Clin Gastroenterol 47 (2013), 461–465.
129. Chaung, K.T., O'Brien, C., Ha, N.B., Nguyen, N.H., Trinh, H.N., Nguyen, M.H., Alternative therapies for chronic hepatitis B patients with partial virological response to standard entecavir monotherapy. J Clin Gastroenterol 50 (2016), 338–344.
130. Viganò, M., Invernizzi, F., Grossi, G., Lampertico, P., Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection. Aliment Pharmacol Ther 44 (2016), 653–661.
131. Chan, H.L., Ahn, S.H., Chuang, W.L., Hui, A.J., Tabak, F., Mehta, R., et al. Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). J Hepatol 62 (2015), S251–S252.
132. Su, W.-W., Hsu, C.-W., Lee, C.-M., Peng, C.-Y., Chuang, W.-L., Kao, J.-H., et al. Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study. J Hepatol, 60, 2014, S47.
133. Xie, Q., Zhou, H., Bai, X., Wu, S., Chen, J.-J., Sheng, J., et al. A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B “e” antigen-positive chronic hepatitis B. Clin Infect Dis 59 (2014), 1714–1723.
134. Brouwer, W.P., Xie, Q., Sonneveld, M.J., Zhang, N., Zhang, Q., Tabak, F., et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 61 (2015), 1512–1522.
135. Ning, Q., Han, M., Sun, Y., Jiang, J., Tan, D., Hou, J., et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 61 (2014), 777–784.
136. Hu, P., Shang, J., Zhang, W., Gong, G., Li, Y., Chen, X., et al. Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon A-2A: A further analysis from new switch study. J Hepatol, 62, 2015, S251.
137. Li, G.-J., Yu, Y.-Q., Chen, S.-L., Fan, P., Shao, L.-Y., Chen, J.-Z., et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrob Agents Chemother 59 (2015), 4121–4128.
138. Chi, H., Xie, Q., Zhang, N.P., Qi, X., Liang, C., Guo, S., et al. Addition of peginterferon alfa-2B during long-term nucleos(T)ide analogue therapy increases hbeag seroconversion and hbsag decline-week 48 results from a multicenter randomized controlled trial (pegon study). Hepatology, 60, 2014, 1106A.
139. Lampertico, P., Brunetto, M.R., Craxì, A., Gaeta, G.B., Rizzetto, M., Palmieri, G., et al. LP25: Add-on peginterferon ALFA-2A significantly reduces hbsag levels in hbeag-negative, genotype d chronic hepatitis b patients fully suppressed on nucleot(s)ide analogue treatment: The HERMES study. J Hepatol, 62, 2015, S276.
140. Bourlière, M., Rabiega, P., Ganne-Carrie, N., Serfaty, L., Marcellin, P., Barthe, Y., et al. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2 (2017), 177–188, 10.1016/S2468-1253(16)30189-3.
141. Wang, F.Y., Li, B., Li, Y., Liu, H., Qu, W.D., Xu, H.W., et al. Entecavir for patients with hepatitis b decompensated cirrhosis in China: a meta-analysis. Sci Rep, 6, 2016, 32722.
142. Zhang, X., Liu, L., Zhang, M., Gao, S., Du, Y., An, Y., et al. The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. Ann Hepatol 14 (2015), 150–160.
143. Miquel, M., Núñez, Ó., Trapero-Marugán, M., Díaz-Sánchez, A., Jiménez, M., Arenas, J., et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 12 (2013), 205–212.
144. Ye, X.-G., Su, Q.-M., Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 19 (2013), 6665–6678.
145. Cholongitas, E., Papatheodoridis, G.V., Goulis, J., Vlachogiannakos, J., Karatapanis, S., Ketikoglou, J., et al. The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. Ann Gastroenterol 28 (2015), 109–117.
146. Yue-Meng, W., Li, Y.H., Wu, H.M., Yang, J., Xu, Y., Yang, L.H., et al. Telbivudine vs. lamivudine and entecavir for treatment-naive decompensated hepatitis B virus-related cirrhosis. Clin Exp Med, 2016, 1–9.
147. Welker, M.-W., Zeuzem, S., Pre- and post-transplant antiviral therapy (HBV, HCV). Visc Med 32 (2016), 105–109.
148. Jang, J.W., Choi, J.Y., Kim, Y.S., Woo, H.Y., Choi, S.K., Lee, C.H., et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 61 (2015), 1809–1820.
149. Hyun, J.J., Seo, Y.S., Yoon, E., Kim, T.H., Kim, D.J., Kang, H.S., et al. Comparison of the efficacies of lamivudine vs. entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 32 (2012), 656–664.
150. Srivastava, M., Rungta, S., Dixit, V.K., Shukla, S.K., Singh, T.B., Jain, A.K., Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: An Indian perspective. Antiviral Res 100 (2013), 300–305.
151. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 64 (2016), 433–485.
152. Perrillo, R., Buti, M., Durand, F., Charlton, M., Gadano, A., Cantisani, G., et al. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver transpl 19 (2013), 887–895.
153. Fox, A.N., Terrault, N.A., The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 56 (2012), 1189–1197.
154. Wang, P., Tam, N., Wang, H., Zheng, H., Chen, P., Wu, L., et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One, 9, 2014, e104480.
155. Fernández, I., Loinaz, C., Hernández, O., Abradelo, M., Manrique, A., Calvo, J., et al. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis 17 (2015), 695–701.
156. Huprikar, S., Danziger-Isakov, L., Ahn, J., Naugler, S., Blumberg, E., Avery, R.K., et al. Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management. Am J Transplant 15 (2015), 1162–1172.
157. European AIDS Clinical Society. Treatment Guidelines 2016;8:1. http://www.eacsociety.org/files/guidelines_8.1-english.pdf.
158. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2016. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
159. Gallant, J., Brunetta, J., Crofoot, G., Benson, P., Mills, A., Brinson, C., et al. Brief report: efficacy and safety of switching to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-1/hepatitis B-coinfected adults. J Acquir Immune Defic Syndr 73 (2016), 294–298.
160. Triantos, C., Kalafateli, M., Nikolopoulou, V., Burroughs, A., Meta-analysis: antiviral treatment for hepatitis D. Aliment Pharmacol Ther 35 (2012), 663–673.
161. Heidrich, B., Yurdaydın, C., Kabaçam, G., Ratsch, B.A., Zachou, K., Bremer, B., et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 60 (2014), 87–97.
162. Wranke, A., Serrano, B.C., Heidrich, B., Kirschner, J., Bremer, B., Lehmann, P., et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology 65 (2017), 414–425.
163. Karaca, C., Soyer, O.M., Baran, B., Ormeci, A.C., Gokturk, S., Aydin, E., et al. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther 18 (2013), 561–566.
164. Heller, T., Rotman, Y., Koh, C., Clark, S., Haynes-Williams, V., Chang, R., et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 40 (2014), 93–104.
165. Wedemeyer, H., Yurdaydin, C., Ernst, S., Caruntu, F.A., Curescu, M.G., Yalcin, K., et al. O4 prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2a plus tenofovir or placebo does not prevent HDVRNA relapse after treatment: the hidit-2 study. J Hepatol 60 (2014), S2–S3.
166. Guedj, J., Rotman, Y., Cotler, S.J., Koh, C., Schmid, P., Albrecht, J., et al. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology 60 (2014), 1902–1910.
167. Keskin, O., Wedemeyer, H., Tüzün, A., Zachou, K., Deda, X., Dalekos, G.N., et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol 13 (2015), 2342–2349.
168. Niro, G.A., Smedile, A., Fontana, R., Olivero, A., Ciancio, A., Valvano, M.R., et al. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Ther 44 (2016), 620–628.
169. Le Gal, F., Brichler, S., Sahli, R., Chevret, S., Gordien, E., First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology 64 (2016), 1483–1494.
170. Manesis, E.K., Vourli, G., Dalekos, G., Vasiliadis, T., Manolaki, N., Hounta, A., et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol 59 (2013), 949–956.
171. Caccamo, G., Saffioti, F., Raimondo, G., Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol 20 (2014), 14559–14567.
172. Konstantinou, D., Deutsch, M., The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol 28 (2015), 221–228.
173. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
174. De Monte, A., Courjon, J., Anty, R., Cua, E., Naqvi, A., Mondain, V., et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 78 (2016), 27–30.
175. Ende, A.R., Kim, N.H., Yeh, M.M., Harper, J., Landis, C.S., Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep, 9, 2015, 164.
176. Collins, J.M., Raphael, K.L., Terry, C., Cartwright, E.J., Pillai, A., Anania, F.A., et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 61 (2015), 1304–1306.
177. Kimura, H., Ohkawa, K., Sakakibara, M., Imanaka, K., Matsunaga, T., Miyazaki, M., et al. Sustained hepatitis C virus RNA clearance accompanied by elevation of hepatitis B virus DNA after short-term peginterferon-α, ribavirin and simeprevir therapy in a chronic hepatitis patient having dual infection with hepatitis B and C viruses. Kanzo 56 (2015), 422–427.
178. Sulkowski, M.S., Chuang, W.-L., Kao, J.-H., Yang, J.C., Gao, B., Brainard, D.M., et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis 63 (2016), 1202–1204.
179. Wang, C., Ji, D., Chen, J., Shao, Q., Li, B., Liu, J., et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol 15 (2017), 132–136.
180. European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol, 66, 2017 [In press].
181. Jochum, C., Maischack, F., Anastasiou, O.E., Verheyen, J., Timm, J., Bechmann, L., et al. Treatment of fulminant acute Hepatitis B with nucles(t)id analogues is safe and does not lead to secondary chronification of Hepatitis B. Z Gastroenterol 54 (2016), 1306–1311.
182. Wang, C.-Y., Zhao, P., Liu, W.-W., Acute Liver Failure Study Team. Acute liver failure caused by severe acute hepatitis B: a case series from a multi-center investigation. Ann Clin Microbiol Antimicrob, 13, 2014, 23.
183. Wong, V.W., Wong, G.L., Yiu, K.K., Chim, A.M., Chu, S.H., Chan, H.-Y., et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol 54 (2011), 236–242.
184. Streinu-Cercel, A., Sandulescu, O., Stefan, M., Streinu-Cercel, A., Treatment with lamivudine and entecavir in severe acute hepatitis B. Indian J Med Microbiol 34 (2016), 166–172.
185. He, B., Zhang, Y., Lü, M.-H., Cao, Y.-L., Fan, Y.-H., Deng, J.-Q., et al. Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis. Eur J Gastroenterol Hepatol 25 (2013), 926–934.
186. Wiegand, J., Wedemeyer, H., Franke, A., Rößler, S., Zeuzem, S., Teuber, G., et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs. placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat 21 (2014), 744–750.
187. Ito, K., Yotsuyanagi, H., Yatsuhashi, H., Karino, Y., Takikawa, Y., Saito, T., et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 59 (2014), 89–97.
188. Goyal, A., Murray, J.M., The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology. PLoS One, 9, 2014, e110143.
189. Sokal, E.M., Paganelli, M., Wirth, S., Socha, P., Vajro, P., Lacaille, F., et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 59 (2013), 814–829.
190. Jonas, M.M., Lok, A.S., McMahon, B.J., Brown, R.S., Wong, J.B., Ahmed, A.T., et al. Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. Hepatology 63 (2016), 307–318.
191. Murray, K.F., Szenborn, L., Wysocki, J., Rossi, S., Corsa, A.C., Dinh, P., et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 56 (2012), 2018–2026.
192. Jonas, M.M., Chang, M.-H., Sokal, E., Schwarz, K.B., Kelly, D., Kim, K.O., et al. Randomized controlled trial of entecavir vs placebo in children with Hepatitis B envelope Ag-positive chronic Hepatitis B. Hepatology 63 (2016), 377–389.
193. Centers for Disease Control and Prevention (CDC), Updated CDC recommendations for the management of hepatitis B virus infected health-care providers and students. MMWR Recomm Rep 61 (2012), 1–12.
194. Gerlich, W.H., Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology 57 (2014), 202–211.
195. Raven, S.F., de Heus, B., Wong, A., Zaaijer, H.L., van Steenbergen, J.E., Fluctuation of viremia in hepatitis B virus-infected healthcare workers performing exposure-prone procedures in the Netherlands. Infect Control Hosp Epidemiol 37 (2016), 655–660.
196. Chen, H.-L., Lee, C.-N., Chang, C.-H., Ni, Y.-H., Shyu, M.-K., Chen, S.-M., et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 62 (2015), 375–386.
197. Greenup, A.-J., Tan, P.K., Nguyen, V., Glass, A., Davison, S., Chatterjee, U., et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 61 (2014), 502–507.
198. Pan, C.Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 374 (2016), 2324–2334.
199. Sun, K.-X., Li, J., Zhu, F.-C., Liu, J.-X., Li, R.-C., Zhai, X.-J., et al. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. Vaccine 30 (2012), 5335–5340.
200. Zou, H., Chen, Y., Duan, Z., Zhang, H., Pan, C., Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat 19 (2012), e18–e25.
201. Wen, W.H., Huang, C.W., Chie, W.C., Yeung, C.Y., Zhao, L.L., Lin, W.T., et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology 64 (2016), 1451–1461.
202. Liu, J., Wang, J., Jin, D., Qi, C., Yan, T., Cao, F., et al. Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus. J Gastroenterol Hepatol 32 (2017), 177–183.
203. Reddy, K.R., Beavers, K.L., Hammond, S.P., Lim, J.K., Falck-Ytter, Y.T., American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148 (2015), 215–219.
204. Huang, H., Li, X., Zhu, J., Ye, S., Zhang, H., Wang, W., et al. Entecavir vs. lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy. Jama, 312, 2014, 2521.
205. Cholongitas, E., Tziomalos, K., Pipili, C., Management of patients with hepatitis B in special populations. World J Gastroenterol 21 (2015), 1738–1748.
206. Viganò, M., Serra, G., Casella, G., Grossi, G., Lampertico, P., Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 16 (2016), 917–926.
207. Phipps, C., Chen, Y., Tan, D., Lymphoproliferative disease and hepatitis B reactivation: challenges in the era of rapidly evolving targeted therapy. Clin Lymphoma Myeloma Leuk 16 (2016), 5–11.
208. Voican, C.S., Mir, O., Loulergue, P., Dhooge, M., Brezault, C., Dréanic, J., et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 27 (2016), 2172–2184.
209. Pattullo, V., Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 22 (2016), 219–237.
210. Grossi, G., Loglio, A., Viganò, M., Cappelletti, M., Goldaniga, M.C., Farina, L., et al. Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma – final results. Hepatology, 64, 2016, 88A.
211. Cerva, C., Colagrossi, L., Maffongelli, G., Salpini, R., Di Carlo, D., Malagnino, V., et al. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect 22 (2016), 946.e1–946.e8.
212. Mozessohn, L., Chan, K.K., Feld, J.J., Hicks, L.K., Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat 22 (2015), 842–849.
213. Huang, Y.H., Hsiao, L.T., Hong, Y.C., Chiou, T.J., Bin, Yu.Y., Gau, J.P., et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31 (2013), 2765–2772.
214. Buti, M., Manzano, M.L., Morillas, R.M., García-Retortillo, M., Martín, L., Prieto, M., et al. Prevents HBV reactivation with tenofovir in Anti-HBC positive patients with hematologic malignancies treated with rituximab. Results final visit 18-months (preblin study). J Hepatol, 64, 2016, S369.
215. Fabrizi, F., Martin, P., Messa, P., Novel perspectives on the hepatitis B virus vaccine in the chronic kidney disease population. Int J Artif Organs 38 (2015), 625–631.
216. Lindemann, M., Zaslavskaya, M., Fiedler, M., Wilde, B., Heinemann, F.M., Heinold, A., et al. Humoral and cellular responses to a single dose of fendrix in renal transplant recipients with non-response to previous hepatitis B vaccination. Scand J Immunol 85 (2017), 51–57.
217. Gajurel, K., Stapleton, J.T., Hepatitis viruses in kidney transplantation. Semin Nephrol 36 (2016), 386–396.
218. Ridruejo, E., Antiviral treatment for chronic hepatitis B in renal transplant patients. World J Hepatol 7 (2015), 189–203.
219. Yap, D.Y., Yung, S., Tang, C.S., Seto, W.K., Ma, M.K., Mok, M.M., et al. Entecavir treatment in kidney transplant recipients infected with hepatitis B. Clin Transplant 28 (2014), 1010–1015.
220. De Virgilio, A., Greco, A., Magliulo, G., Gallo, A., Ruoppolo, G., Conte, M., et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev 15 (2016), 564–570.
221. Boyd, A., Lacombe, K., Lavocat, F., Maylin, S., Miailhes, P., Lascoux-Combe, C., et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol 65 (2016), 683–691.
222. Lai, C.-L., Wong, D., Ip, P., Kopaniszen, M., Seto, W.-K., Fung, J., et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol 66 (2017), 275–281.
223. Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., Dandri, M., et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 51 (2009), 581–592.
224. Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64 (2015), 1972–1984.
225. Zoulim, F., Testoni, B., Lebossé, F., Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies. Clin Gastroenterol Hepatol 11 (2013), 1011–1013.
226. Park, Y., Hong, D.J., Shin, S., Cho, Y., Kim, H.-S., Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay. Am J Clin Pathol 137 (2012), 770–777.
227. Luckenbaugh, L., Kitrinos, K.M., Delaney, W.E., Hu, J., Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy. J Viral Hepat 22 (2015), 561–570.
228. Honda, M., Shirasaki, T., Terashima, T., Kawaguchi, K., Nakamura, M., Oishi, N., et al. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis 213 (2016), 1096–1106.
229. Wong, D.K., Seto, W.-K., Cheung, K.-S., Chong, C.-K., Huang, F.-Y., Fung, J., et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int, 2017 (in press).
230. Maasoumy, B., Wiegand, S.B., Jaroszewicz, J., Bremer, B., Lehmann, P., Deterding, K., et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect, 21, 2015, 606, e1–e10.
231. Tada, T., Kumada, T., Toyoda, H., Kiriyama, S., Tanikawa, M., Hisanaga, Y., et al. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol 65 (2016), 48–56.
232. Song, G., Yang, R., Rao, H., Feng, B., Ma, H., Jin, Q., et al. Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol 89 (2017), 463–468.
233. Tanaka, E., Matsumoto, A., Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res 44 (2014), 1–8.
234. Martinot-Peignoux, M., Lapalus, M., Maylin, S., Boyer, N., Castelnau, C., Giuily, N., et al. Baseline HBsAg and HBcrAg titres allow peginterferon-based “precision medicine” in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 23 (2016), 905–911.
235. Chuaypen, N., Posuwan, N., Payungporn, S., Tanaka, Y., Shinkai, N., Poovorawan, Y., et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 36 (2016), 827–836.
236. Wang, J., Shen, T., Huang, X., Kumar, G.R., Chen, X., Zeng, Z., et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 65 (2016), 700–710.
237. Giersch, K., Allweiss, L., Volz, T., Dandri, M., Lütgehetmann, M., Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol 66 (2016), 460–462.
238. Wang, J., Du, M., Huang, H., Chen, R., Niu, J., Jiang, J., et al. Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”: Consistent loss of serum HBV RNA might predict the “para-functional cure” of chronic hepatitis B. J Hepatol 66 (2017), 462–463.
239. Van Bömmel, F., Van Bömmel, A., Krauel, A., He, H., Wat, C., Pavlovic, V., et al. Serum HBV RNA is an early predictor of HBeAg seroconversion in patients with chronic Hepatitis B (CHB) treated with pegylated interferon alfa-2a (40KD). Hepatology, 62, 2015, 336A.
240. van Bömmel, F., Bartens, A., Mysickova, A., Hofmann, J., Krüger, D.H., Berg, T., et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61 (2015), 66–76.
241. Zeisel, M.B., Lucifora, J., Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 64 (2015), 1–13.
242. Lok, A.S., Zoulim, F., Dusheiko, G., Ghany, M.G., Hepatitis B cure: from discovery to regulatory approval. J Hepatol, 2017, 10.1016/j.jhep.2017.05.008 in press.
243. Durantel, D., Zoulim, F., New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. J Hepatol 64 (2016), S117–S131.
244. Bogomolov, P., Alexandrov, A., Voronkova, N., Macievich, M., Kokina, K., Petrachenkova, M., et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol 65 (2016), 490–498.
245. Blank, A., Markert, C., Hohmann, N., Carls, A., Mikus, G., Lehr, T., et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol 65 (2016), 483–489.
246. Al-Mahtab, M., Bazinet, M., Vaillant, A., Ip, P., Huang, F.-Y., Lai, C.-L., et al. Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS One, 11, 2016, e0156667.
247. Koh, C., Canini, L., Dahari, H., Zhao, X., Uprichard, S.L., Haynes-Williams, V., et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis 15 (2015), 1167–1174.